期刊文献+

人巨细胞病毒gB基因的构建、表达及鉴定

Construction,expression and identification of the gBgene of human cytomegalovirus
在线阅读 下载PDF
导出
摘要 目的构建人巨细胞病毒(HCMV)gB基因,并对pET28a/gB重组质粒进行诱导表达,鉴定表达的目的蛋白。方法根据Genebank中HCMV核苷酸序列设计引物,并在引物的5′、3′端分别加入BamHⅠ、EcoRⅠ限制性内切酶位点。特异性扩增gB编码基因片段,同时构建含HCMVgB编码基因的原核表达载体,对重组质粒进行诱导表达,用间接酶联免疫吸附测定(ELISA)法对纯化的Ni/gB融合蛋白的灵敏度和特异度等生物活性进行鉴定,灵敏度可达95%,特异度达96.7%。结果目的蛋白经诱导后表达于上清液中,经鉴定,目的蛋白保留了天然蛋白原有的生物活性。结论 Ni/gB融合蛋白的获得,为研制以重组蛋白代替传统全病毒作为检测抗原的新型HCMV特异性免疫学检测试剂盒奠定了基础。 Objective To construct and identify the procaryotic expression vector of gB. Trying to induce the pET28a/gB and i- dentify the expressed protein. Methods According to the nucleotide sequence of HCMV in Genbank,a pair of primers with BarnH I and EcoR I sites at 5r-terminal 3'-terminal were designed and synthesized respectively and a HCMV gB DNA fragment was am- pli/ied by PCR. The amplified gB gene fragment was subcloned into pET28a vector by a series of molecular biological methods in- cluding restriction digest and ligation, and transfection. The recombinant plasmid was induced under optimum conditions, then the expressed production was identified by SDS-PAGE. The recombinant strain was lyzed by ultrasonic and harvested by centrifugation. The sensitivity(95 %) and specificity(96.7%) of pET28a/gB protein were identified by indirect ELISA. Results The interest pro- tein was found in the supernatant,and its original biological activity is retained when compared with native protein. Conclusion The pET28a/gB protein was successfully expressed and it is a solid foundation for developing new type-specific serological detection of HCMV.
出处 《国际检验医学杂志》 CAS 2014年第4期390-391,393,共3页 International Journal of Laboratory Medicine
关键词 巨细胞病毒 载体 重组蛋白质类 cytomegalovirus victor recombinant proteins
  • 相关文献

参考文献7

二级参考文献17

  • 1Levi M, Ruden U, Wahren B, et al. Peptide sequences of glycoprotein G-2 discriminate between herpes simplex virus type 2 (HSV2) and HSV1 antibodies. Clin Diagn Lab Immunol, 1996, 3(3): 265-269.
  • 2Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin lnfect Dis, 1998, 26(3): 541-555.
  • 3Straus SE, Croen KD, Sawyer MH, et al. Acyclovir suppression of frequently recurring genital herpes: efficacy and diminishing need during successive years of treatment. JAMA, 1988, 260(15): 2227-2230.
  • 4Kaplowitz LG, Baker D, Gelb L, et al. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection.The acyclovir study group. JAMA, 1991, 265(6): 747-751.
  • 5Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis, 2000, 30(3): 549-566.
  • 6Whitley RJ, Roizman B. Herpes simplex viruses: is a vaccine tenable? J Clin lnvest, 2002, 110(2): 145-151.
  • 7Lilie H, Schwarz E, Rudolph R. Advances in refolding of proteins produced in E. coil Curr Opin Biotechnol, 1998, 9(5): 497-501.
  • 8Andersen DC, Krummen L. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol, 2002, 13(2): 117-123.
  • 9Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol, 2004, 6(5): 401-410.
  • 10Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein D adjuvant vaccine to prevent genital herpes. NEngl JMed, 2002, 347(21): 1652-1661.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部